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Purpose: Glioblastoma (GBM) is a locally aggressive radioresistant brain tumor with poor prognosis. Previous preclinical studies using an intracranial model of GBM demonstrated Pulsed-RT (PRT)+ concomitant TMZ was a novel and effective first-line therapy. The aim of the current study was to evaluate if inhibitors of DNA base excision repair (BER) could further increase the efficacy of PRT+TMZ therapy for the treatment of GBM. The BER pathway is a major contributor to TMZ cellular resistance, so inhibition of this pathway could re-sensitize TMZ resistant tumors and improve radiation efficacy. . No significant decreases in normalized tumor volume were noted until 10 d post-RT in the PRT+TMZ cohort (38.2%, p=0.06) although most tumors demonstrated some measure of growth delay through 26 d. By study endpoint, tumors increased 2-3 fold in all surviving animals. There was no significant change in median survival in all irradiated groups (95 to 109 days). CUR alone did not benefit survival (median 21.5±3.3 d), similar to untreated animals (18.4 days±1.1).
Materials and Methods
Conclusion: BER inhibitors increased cell killing when RT was combined with TMZ, and were equally effective in the PRT and SRT-based combinations. CUR and DDN were the most effective BER inhibitors in vitro. In vivo, CUR alone was not effective at preventing tumor growth or improving survival. CUR increased the effectiveness of TMZ as determined by slower tumor growth rates, however all benefit was lost was 26 days post Tx. The data support the development of combinational regimes of BER inhibitors with RT+TMZ in an effort to improve patient outcomes.
